Asim Kr Debnath, 702100 Linwood Ave, West Fort Lee, NJ 07024
Asim Debnath Phones & Addresses
2100 Linwood Ave, Fort Lee, NJ 07024 201-3461277
2100 Linwood Ave APT 21T, Fort Lee, NJ 07024 201-3461277
Claremont, CA
New York, NY
2100 Linwood Ave APT 21T, Fort Lee, NJ 07024 201-2648024
Work
Position:
Private Household Service Occupations
Education
Degree:
Bachelor's degree or higher
Mentions for Asim Kr Debnath
Publications & IP owners
Us Patents
Screening Of Antiviral Compounds Targeted To The Hiv-1 Gp41 Core Structure
US Patent:
6596497, Jul 22, 2003
Filed:
Mar 14, 2000
Appl. No.:
09/525874
Inventors:
Shibo Jiang - Jackson Heights NY
Asim K. Debnath - Fort Lee NJ
Asim K. Debnath - Fort Lee NJ
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
G01N 3353
US Classification:
435 71, 4241601, 435 4, 435 5, 435 772, 435 792, 435 793, 435 794, 436501, 5303881, 5303883, 5303891, 5303894
Abstract:
A method for the screening of antiviral compounds targeted to the HIV gp41 core structure comprising capturing polyclonal antibodies from an animal other than a mouse directed against a trimer of a heterodimer containing an N-peptide and a C-peptide onto a solid-phase, mixing a compound to be tested with an N-peptide and then adding a C-peptide, adding the resultant mixture to the resultant polyclonal antibody coated solid-phase and then removing unbound peptides and unbound compound, adding a monoclonal antibody directed against the trimer of a heterodimer containing an N-peptide and a C-peptide and measuring the antibody binding of the monoclonal antibody. A method for inhibiting HIV-1 virus replication or infectivity in a patient by administering to the patient an antiviral compound targeted to the HIV-1 gp41 core structure selected from the group consisting of 7-[6-phenylamino-4[4-[(3,5-disulfo-8-hydroxynaphthyl)azo]-2-methoxy-5-methyl-phenylamino]-1,3,5-triazine-2-yl]-4-hydroxy-3-[(2-methoxy-5-sulfophenyl)azo]-2-naphthalene sulfonic acid and 5-[(4-chloro-6-phenylamino-1,3,5-triazine-2-yl)-amino]-4-hydroxy-3-[(4-methyl-5-sulfophenyl)azo]-2,7-naphthalene disulfonic acid.
Methods For Preventing Hiv-1 Or Hiv-2 Infection
US Patent:
6727240, Apr 27, 2004
Filed:
Oct 21, 1994
Appl. No.:
08/342745
Inventors:
Alexander R. Neurath - New York NY
Shibo Jiang - New York NY
Asim Kumar Debnath - New York NY
Shibo Jiang - New York NY
Asim Kumar Debnath - New York NY
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
A61K 31555
US Classification:
514185
Abstract:
A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof.
Compounds For Inhibition Of Hiv Infection By Blocking Hiv Entry
US Patent:
7241803, Jul 10, 2007
Filed:
Nov 12, 2003
Appl. No.:
10/706027
Inventors:
Shibo Jiang - Fresh Meadows NY, US
Asim Kumar Debnath - Fort Lee NJ, US
Asim Kumar Debnath - Fort Lee NJ, US
Assignee:
New York Blood Center - New York NY
International Classification:
C07D 207/327
A61K 31/402
A61K 31/402
US Classification:
514427, 548560, 548563
Abstract:
A group of compounds that inhibit HIV replication by blocking HIV entry was identified. Two representative compounds, designated NB-2 and NB-64, inhibited HIV replication (p24 production) with ICvalues
Small Molecule Inhibitors Of Retroviral Assembly And Maturation
US Patent:
8299093, Oct 30, 2012
Filed:
Aug 6, 2009
Appl. No.:
12/536738
Inventors:
Asim Kumar Debnath - Fort Lee NJ, US
Hongtao Zhang - Oakland Gardens NY, US
Francesca Curreli - Bronx NY, US
Hongtao Zhang - Oakland Gardens NY, US
Francesca Curreli - Bronx NY, US
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
A61K 31/47
US Classification:
514312
Abstract:
Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection.
Antiviral Cell-Penetrating Peptides
US Patent:
8324153, Dec 4, 2012
Filed:
May 5, 2009
Appl. No.:
12/436080
Inventors:
Asim Kumar Debnath - Fort Lee NJ, US
Hongtao Zhang - Mt. Vernon NY, US
Francesca Curreli - Bronx NY, US
Hongtao Zhang - Mt. Vernon NY, US
Francesca Curreli - Bronx NY, US
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
A61K 35/14
A61K 38/36
A61K 38/00
A61K 51/00
C07K 14/745
A61K 38/36
A61K 38/00
A61K 51/00
C07K 14/745
US Classification:
514 22, 530381, 514 11, 424 169
Abstract:
Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
Small Molecule Inhibitors Of Retroviral Assembly And Maturation
US Patent:
8546439, Oct 1, 2013
Filed:
Sep 14, 2012
Appl. No.:
13/616710
Inventors:
Asim Kumar Debnath - Fort Lee NJ, US
Hongtao Zhang - Mt. Vernon NY, US
Francesca Curreli - Bronx NY, US
Hongtao Zhang - Mt. Vernon NY, US
Francesca Curreli - Bronx NY, US
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
A61K 31/415
A61K 31/535
A61K 31/497
A61K 31/445
A61K 31/535
A61K 31/497
A61K 31/445
US Classification:
514387, 5142358, 51425401, 514322
Abstract:
Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection.
Anti-Viral Compositions Comprising Heterocyclic Substituted Phenyl Furans And Related Compounds
US Patent:
2006028, Dec 21, 2006
Filed:
Jun 6, 2006
Appl. No.:
11/448439
Inventors:
Shibo Jiang - Fresh Meadows NY, US
Asim Debnath - Fort Lee NJ, US
Hong Lu - Bayside NY, US
Asim Debnath - Fort Lee NJ, US
Hong Lu - Bayside NY, US
International Classification:
A61K 31/53
A61K 31/501
A61K 31/497
A61K 31/496
A61K 31/4439
A61K 31/427
A61K 31/501
A61K 31/497
A61K 31/496
A61K 31/4439
A61K 31/427
US Classification:
514241000, 514252130, 514255050, 514252020, 514252050, 514369000, 514253090, 514341000, 514342000
Abstract:
A group of compounds that inhibit HIV replication by blocking HIV entry was identified. One representative compound, designated NB-206, and its analogs inhibited HIV replication (p24 production) with ICvalues at nanomolar levels. It was proved that NB-206 and its analogs are HIV entry inhibitors by targeting the HIV gp41 since: 1) they inhibited HIV-mediated cell fusion; 2) they inhibited HIV replication only when they were added to the cells less than one hour after virus addition; 3) they blocked the formation of the gp41 core that is detected by sandwich enzyme linked immunosorbent assay (ELISA) using a conformation-specific MAb NC-1; and 4) they inhibited the formation of the gp41 six-helix bundle revealed by fluorescence native-polyacrylamide gel electrophoresis (FN-PAGE). These results suggested that NB-206 and its analogs may interact with the hydrophobic cavity and block the formation of the fusion-active gp41 coiled coil domain, resulting in inhibition of HIV-1 mediated membrane fusion and virus entry.
Compounds For Inhibition Of Hiv Infection By Blocking Hiv Entry
US Patent:
2007023, Oct 4, 2007
Filed:
May 24, 2007
Appl. No.:
11/753244
Inventors:
Shibo Jiang - Fresh Meadows NY, US
Asim Debnath - Fort Lee NJ, US
Asim Debnath - Fort Lee NJ, US
International Classification:
C07D 207/30
A61K 31/00
A61K 31/40
A61K 31/00
A61K 31/40
US Classification:
514429000, 514001000, 548563000
Abstract:
A group of compounds that inhibit HIV replication by blocking HIV entry was identified. Two representative compounds, designated NB-2 and NB-64, inhibited HIV replication (p24 production) with ICvalues
Possible Relatives
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.